KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Free Cash Flow (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Free Cash Flow for 17 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 60.5% to $1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $12.8 billion, a 7.87% decrease, with the full-year FY2025 number at $12.8 billion, down 7.87% from a year prior.
  • Free Cash Flow was $1.6 billion for Q4 2025 at Bristol Myers Squibb, down from $6.0 billion in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $6.0 billion in Q3 2025 to a low of $1.6 billion in Q4 2025.
  • A 5-year average of $3.3 billion and a median of $3.5 billion in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 136.33% in 2021, then tumbled 60.5% in 2025.
  • Bristol Myers Squibb's Free Cash Flow stood at $3.7 billion in 2021, then decreased by 20.79% to $3.0 billion in 2022, then surged by 32.5% to $3.9 billion in 2023, then increased by 3.54% to $4.1 billion in 2024, then tumbled by 60.5% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Free Cash Flow are $1.6 billion (Q4 2025), $6.0 billion (Q3 2025), and $3.6 billion (Q2 2025).